Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to License ABI's RT-PCR Thermal Cycler IP as Part of Settlement

NEW YORK (GenomeWeb News) — Applied Biosystems and Agilent have settled their patent suit concerning real-time thermal cycler IP and have forged a licensing arrangement, ABI said yesterday.
Under the agreement, Agilent will license “certain Applera technology” relating to Agilent’s real-time thermal cycler instruments for research use, but not in vitro diagnostics. Agilent will also license Applera technology relating to Agilent’s PCR and real-time enzymes and kits.
The settlement lifts injunctions in Germany and the Netherlands and pending cases in the US and France, and the settlement and agreement “fully resolve all pending disputes” between the companies.
The suit began in May 2007 when ABI parent Applera sued Stratagene, now part of Agilent, for alleging that Stratagene's Mx3000P, Mx3005P, Mx4000P, and "certain related reagents" infringe ABI’s EU patent No. 0 872 562 B1.
Stratagene at the time claimed that ABI’s claims were “without merit” and said it intended to “vigorously defend these actions.”
ABI today said that these agreements fully resolve all pending disputes between Applera and Stratagene.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.